Cancer incidence in patients with systemic lupus erythematosus SLE is higher compared with the general population, especially in younger women, according to research results published in Arthritis Care and Research. Researchers conducted a retrospective, multicenter study using patient data from the SLE Registry of the Spanish Society of Rheumatology. With these data, investigators aimed to estimate cancer incidence in patients with SLE and to analyze the factors associated with cancer onset, differentiating between hormone-sensitive and nonhormone-sensitive cancers. In total, patients 4. The accumulated rates of incidence of cancer in patients with SLE were 6.
Higher Risk for Cancer in Younger Women With Systemic Lupus Erythematosus
Higher Risk for Cancer in Younger Women With Systemic Lupus Erythematosus - Rheumatology Advisor
Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study. Although accumulating data have suggested the development of cancer in systemic lupus erythematosus SLE patients, these results remain inconsistent. To examine such a putative association, this analysis reports the association between SLE and the risks of 24 cancer types. A total of 24 eligible studies were ultimately enrolled. Additionally, SLE could reduce the risk of prostate cancer and cutaneous melanoma; however, it was not significantly associated with breast, uterus, ovarian, pancreatic, colorectal, or brain cancers.
In Lupus, Risks for Cancers Rise
Specifically, lupus patients may experience an elevated risk of lymphoma and other cancers, such as cancer of the cervix. Researchers have elucidated certain connections between lupus and cancer. For example, it is widely accepted that immunosuppressive medications, such as azathioprine Imuran and mycophenolate mofetil Cellcept contribute to elevated cancer risk. However, one of the largest studies to investigate this connection suggests that the risk of cancer is actually greatest during the earlier stages of lupus, indicating that exposure to immunosuppressive therapy is not the only link between lupus and cancer.
We determined whether any individual cancers are increased or decreased in a cohort of patients with systemic lupus erythematosus SLE followed for up to 32 years at the University College London Hospitals Lupus Clinic, looking for any associated clinical or serological factors and the prognosis after cancer diagnosis. We undertook a careful retrospective review of the medical records and identified all individuals diagnosed with cancer. For controls, we selected three other patients in the cohort who had not developed cancer, carefully matched for age, sex, ethnicity and disease duration, to determine if any obvious differences emerged in a nested case-control design. Thirty-three patients developed cancer after being diagnosed with SLE. There was a statistically insignificant small increase in overall cancer risk, standardized incidence ratios SIRs 1.